Baird analyst Brian Skorney elevated Neurocrine to Fresh Pick and said to take advantage of the unwarranted fear caused by the FDA's FAERS update. The analyst said the update was a regular update to their database and it did yield a numerically higher number of patient deaths. However, he said this is typical because as the number of Ingrezza prescriptions increase, so will the number of incidents. He believes this caused an overreaction and investors should take advantage of the buying opportunity. Skorney reiterated his Outperform rating and $131 price target on Neurocrine shares.